Investigating how pizza delivery boy contracted coronavirus, says South Delhi DM

Bengaluru, Apr 30: Shares of Glenmark Pharmaceuticals Ltd rose almost 9% on Thursday after the Indian drugmaker got an approval to conduct clinical trials with antiviral drug favipiravir, seen as a potential treatment for COVID-19.

Favipiravir, manufactured under the brand name Avigan by a unit of Japan's Fujifilm Holdings Corp and approved for use as an anti-flu drug in the Asian island country in 2014, has been effective, with no obvious side-effects, in helping coronavirus patients recover, a Chinese official told reporters at a news conference last month.

"After having successfully developed the API and the formulations ... Glenmark is all geared to immediately begin clinical trials on favipiravir on COVID-19 patients in India," Sushrut Kulkarni, executive vice-president for Global R&D, Glenmark Pharmaceuticals, said in a statement. 

The Drug Controller General of India, the country's drug regulator, did not immediately respond to Reuters request for comment.

On Wednesday, another Indian pharmaceutical company, Strides Pharma Science Ltd, said it had developed and commercialized favipiravir antiviral tablets, and had applied to Indian drug authorities to start trials.

Shares of Mumbai-based Glenmark Pharmaceuticals, which rose as much as 8.9% to 359 rupees ($4.78), was trading up 5.9%, as of 0407 GMT.

New Delhi, Jun 23: "Coming up with a clinically tested, evidence-based medicine was a challenge," said Yoga Guru Ramdev as on Tuesday he launched Patanjali's Coronil tablet, which he claims is a cure for COVID-19. He also talked about various other immunity boosters at an event here during the launch.

Patanjali claims those administered the medicine were fully cured and none died. Ramdev even claimed that 69 per cent of them recovered within 3 days.

"We appointed a team of scientists after COVID-19 outbreak," said Balkrishna, Ramdev's close aide and MD of Patanjali Ayurved. He added that Patanjali conducted a clinical case study on hundreds of positive patients.

Patanjali has claimed that the clinical trials which were controlled in nature, was jointly conducted by Patanjali Research Institute which is based out of Haridwar and the National Institute of Medical Sciences, Jaipur.

Talking about the clinical trials, Ramdev said, "Under this 280 patients were included and 100 per cent of those recovered." He added they were able to control Coronavirus and its complications.

He said that in the next few days, data of the trail will be released as evidence to bolster claims. There are now over 9 million people affected by the pandemic since it broke out in China's Wuhan city in December 2019.

He said Ayurvedic elements are being used in the tablet. "There are more than 100 compounds used in the Coronil," he added. An entire kit is being made for that which consists of other Ayurvedic medicine as well which helps in immunity. The entire kit comes at Rs 600. However, he claimed that it will be given for free to those living below the poverty line.

As for doses, Panajali prescribes: "2-2 tablets should be consumed with hot water half an hour after meals. The above mentioned drug intake and quantity is suitable for people between 15 to 80 years of age. Half the amount of the above mentioned medicines can be used for children between the age of 6 to 14 years." These are the written instructions on the pack.

India has been battling the pandemic with close to 4 lakh cases in India on Tuesday and around 14,000 deaths so far.

Bengaluru, Jul 1: A day after the Government banned several Chinese apps, popular short-form video app Mitron reported that its daily traffic jumped up by more than 11 times.

Just 5 days after crossing the 10 million (1 crore) downloads milestone, Mitron has now announced that the app has been downloaded by 17 million (1.7 crore) users in India. Mitron app has been one of the most downloaded apps in India during the last two months.

"It is incredibly exciting to see the rapid adoption of Mitron by Indian users. 11-fold jump in traffic, immediately after the ban of Chinese apps, was beyond our expectations," said Shivank Agarwal, Founder, and CEO, Mitron.

Anish Khandelwal, Founder and CTO said, " We have built a solid backend infrastructure and our platform is now completely scalable and autonomous and that is helping us to cater to the sharp rise in traffic on Mitron App."

Mitron has been rapidly enhancing the product with several improvements for the users including an updated video upload process that is much easier, enhanced audio library with a wide choice of Indian content, and a feature that enables users to flag any inappropriate content easily.

Users uploaded millions of videos in 10 different languages and the number of videos viewed on the platform increased sharply to cross 30 million video views per hour.

Shivank added "We are a young company and we are hiring some of the best product & engineering talent to scale up Mitron rapidly. We are confident that we can build Mitron into one of the best apps in the short-form video space. Our focus is on building features and content that uniquely resonates with Indian users, while being sensitive to community standards and local laws in India and we believe that will help us build Mitron into a very large business."

Founded by two Computer Science engineers, Shivank Agarwal (alumnus of IIT Roorkee) and Anish Khandelwal (alumnus of Visvesvaraya National Institute of Technology), Mitron app is a short-form video app that allows users to create, upload and view entertaining short videos.